Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential DLI and CIK Cells for Relapsed Hematologic Malignancies
NCT01186809Phase 2Completed
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Jul 2009
- Primary completion
- Sep 2016
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of unmodified CIK in hematologic malignancy, sponsored by Papa Giovanni XXIII Hospital. Started Jul 2009; status: completed.
02
Drugs
unmodified CIK
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT01186809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01186809.